The result of numerous enzymatic processes, many of which are dysregulated in pathological situations, is adenosine monophosphate [1].

Absorption, Distribution and Excretion
Following oral administration of amphetamine to rats, it is completely recovered from the bloodstream. It appears rapidly in the blood (within 15–30 minutes) and distributes rapidly, as plasma concentrations decrease fivefold within 2 hours.

[1]. Mondal S, et al. Utility of Adenosine Monophosphate Detection System for Monitoring the Activities of Diverse Enzyme Reactions. Assay Drug Dev Technol. 2017 Oct/Nov;15(7):330-341.

Adenanthin 5'-monophosphate is a purine nucleoside 5'-monophosphate with the nucleobase adenine. It has multiple functions, including as an EC 3.1.3.11 (fructose diphosphatase) inhibitor, an EC 3.1.3.1 (alkaline phosphatase) inhibitor, an Adenanthin A1 receptor agonist, a nutritional supplement, a micronutrient, a basic metabolite, and a cofactor. It is both Adenanthin 5'-phosphate and a purine nucleoside 5'-monophosphate. It is the conjugate base of Adenanthin 5'-monophosphate (1+). It is the conjugate acid of Adenanthin 5'-monophosphate (2-). Adenanthin phosphate, or Adenanthin acid, is an adenine nucleotide in which a phosphate group is esterified at the 2', 3', or 5' position of the sugar moiety. Because Adenanthin phosphate was considered neither safe nor effective, it was withdrawn by the U.S. Food and Drug Administration (FDA) because it was not suitable for its intended use as a vasodilator and anti-inflammatory agent.
Adenanthin monophosphate (AMAP) is a metabolite found in or produced by Escherichia coli (K12 strain, MG1655 strain).
AMAP has been reported in Drosophila melanogaster, silkworm, and other organisms with relevant data.
AMAP is a metabolite found in or produced by Saccharomyces cerevisiae.
Adenine nucleotides have a phosphate group esterified at the 2', 3', or 5' position of their sugar moiety.
See also: Poly AU (monomer).
Pharmacological Indications
For nutritional supplementation, and also for the treatment of dietary deficiencies or imbalances.
Mechanism of Action
Nucleotides such as Adenanthin-5'-monophosphate affect a variety of immune functions, including reversing immunosuppression caused by malnutrition and starvation, enhancing T cell maturation and function, enhancing natural killer cell activity, improving delayed-type hypersensitivity reactions, enhancing resistance to infectious pathogens such as Staphylococcus aureus and Candida albicans, and regulating the response of T cells to type 1 CD4 helper lymphocytes (Th1 cells). Studies have shown that mice fed a nucleotide-free diet exhibit impaired humoral and cellular immune responses. Supplementation with dietary nucleotides can restore both immune responses to normal. These studies used RNA (the delivery form of nucleotides) and ribonucleotides. The mechanism by which nucleic acids/nucleotides enhance immune activity remains unclear.

---

Therapeutic Uses
Energy-rich phosphates are the "energy pool" for cells to obtain energy. Specific assays of nucleotides have diagnostic value in pathological conditions involving altered metabolism and are increasingly used in the diagnosis of heart, liver, and kidney diseases.

---

Pharmacodynamics
Adenanthin monophosphate (AMP), also known as 5'-Adenanthin, is a nucleotide found in RNA. It is an ester formed from a phosphate group and the nucleoside Adenanthin. AMP consists of a phosphate group, a pentose ribose, and the nucleobase adenine. AMP can be used as a dietary supplement to enhance immune activity and as a sugar substitute to help maintain a low-calorie diet.

C10H14N5O7P

347.2212

347.063

61-19-8

24937-83-5

6083

CRYSTALS FROM WATER + ACETONE
POWDER, NEEDLES FROM WATER & DIL ALC

2.3±0.1 g/cm3

798.5±70.0 °C at 760 mmHg

178-185 °C

436.7±35.7 °C

0.0±3.0 mmHg at 25°C

1.905

-0.22

5

11

4

23

481

4

P(=O)(O[H])(O[H])OC([H])([H])[C@]1([H])[C@]([H])([C@]([H])([C@]([H])(N2C([H])=NC3=C(N([H])[H])N=C([H])N=C23)O1)O[H])O[H]

UDMBCSSLTHHNCD-KQYNXXCUSA-N

InChI=1S/C10H14N5O7P/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(17)6(16)4(22-10)1-21-23(18,19)20/h2-4,6-7,10,16-17H,1H2,(H2,11,12,13)(H2,18,19,20)/t4-,6-,7-,10-/m1/s1

[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate

2934.99.9001

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.

Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

DMSO : ~16.67 mg/mL (~48.01 mM)
H2O : ~1.67 mg/mL (~4.81 mM)

Solubility in Formulation 1: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

---

Solubility in Formulation 2: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

---

View More

Solubility in Formulation 3: ≥ 1.67 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

---

Solubility in Formulation 4: 3.33 mg/mL (9.59 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C).

---

 (Please use freshly prepared in vivo formulations for optimal results.)